- Current report filing (8-K)
June 23 2011 - 7:10AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of
the Securities Exchange Act of 1934
Date of Report (Date of Earliest event Reported): June 23, 2011
(June 20, 2011)
CHINA BIOLOGIC PRODUCTS, INC.
(Exact name of registrant as specified in its charter)
Delaware
|
001-34566
|
75-2308816
|
(State or other jurisdiction of
|
(Commission File No.)
|
(IRS Employer ID No.)
|
incorporation or organization)
|
|
|
No. 14 East Hushan Road,
Tai'an City, Shandong,
271000
People's Republic of China
(Address of Principal
Executive Offices)
86-538 -620-2306
Registrant's telephone number,
including area code
_____________________________
(Former name or former address,
if changed since last report)
Check the appropriate box below if the Form 8-K filing is
intended to simultaneously satisfy the filing obligation of the registrant under
any of the following provisions (
see
General Instruction A.2. below):
[ ] Written communications pursuant to Rule 425 under the
Securities Act (17 CFR 230.425)
[ ] Soliciting material pursuant to Rule 14a-12 under the
Exchange Act (17 CFR 240.14a -12)
[ ] Pre-commencement communications pursuant to Rule
14d-2(b) under the Exchange Act (17 CFR 240.14d -2(b))
[ ] Pre-commencement communications pursuant to Rule
13e-4(c) under the Exchange Act (17 CFR 240.13e -4(c))
Item 5.07 Submission of Matters to a Vote of Security
Holders.
China Biologic Products, Inc. (the Company) held its 2011
Annual Shareholders Meeting on Monday, June 20, 2011. Proxies for the Annual
Meeting were solicited pursuant to the Company's proxy statement filed on April
29, 2011 with the Securities and Exchange Commission under Section 14(a) of the
Securities Exchange Act of 1934 (the "Proxy Statement").
The Companys shareholders considered four proposals, each of
which is described in the Proxy Statement. A total of 15,702,098 shares were
represented in person or by proxy, or 64.5% of the total shares outstanding. The
final results of votes with respect to the proposals submitted for shareholder
vote at the Annual Meeting are set forth below.
Proposal 1 - Election of Directors
Shareholders elected Siu Ling Chan, Sean Shao, Xiangmin Cui,
Tong Jun Lin, Chong Yang Li, Bing Li and Wenfang Liu as Directors as
follows:
Director
|
For
|
Abstain
|
Siu Ling Chan
|
15,696,556
|
5,542
|
Sean Shao
|
15,619,606
|
82,492
|
Xiangmin Cui
|
15,693,170
|
8,928
|
Tong Jun
Lin
|
11,100,546
|
4,601,552
|
Chong Yang Li
|
14,874,769
|
827,329
|
Bing Li
|
15,699,056
|
3,042
|
Wenfang Liu
|
11,106,432
|
4,595,666
|
Proposal 2 - Ratification of the Appointment of the
Company
s Independent Registered Public Accounting Firm
Shareholders approved ratification of the appointment of KPMG
as the Companys independent public accounting firm for the fiscal year ending
December 31, 2011.
For
|
Against
|
Abstain
|
15,696,866
|
3,220
|
2,012
|
Proposal 3 Advisory Vote on Executive Compensation
Shareholders approved the executive compensation.
For
|
Against
|
Abstain
|
11,096,524
|
4,598,887
|
6,687
|
Proposal 4 Advisory Vote on the Frequency of an
Advisory Vote on Executive Compensation
Shareholders approved having an advisory vote every year on
executive compensation.
Every
year
|
Every two years
|
Every three years
|
Abstain
|
11,062,944
|
3,665
|
36,548
|
4,598,941
|
There were no broker non-votes for any of the proposals
submitted for shareholder vote at the Annual Meeting.
- 2 -
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of
1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.
Date: June 23, 2011
|
CHINA BIOLOGIC PRODUCTS, INC.
|
|
|
|
|
|
By: /
s/ Chao Ming
Zhao
|
|
Chao Ming Zhao
|
|
Chief Executive
Officer
|
- 3 -
China Bioligic Products (NASDAQ:CBPO)
Historical Stock Chart
From Jun 2024 to Jul 2024
China Bioligic Products (NASDAQ:CBPO)
Historical Stock Chart
From Jul 2023 to Jul 2024